# SpectraCure > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/spectracure). ## Overview SpectraCure is a Swedish medical technology company based in Lund that develops a proprietary photodynamic therapy system for treating localized prostate cancer. Its platform combines a laser-based treatment device, a photosensitive drug, and patented dose-control software under the Q-PRO and IDOSE® names, with the same core technology designed to be adaptable to other solid tumors. ## Products & services • Q-PRO® interstitial PDT treatment system • IDOSE® patented dose-control software • Laser-based photodynamic cancer therapy • Clinical development for localized prostate cancer • Platform adaptation for other solid tumors - **Treatment system hardware** (40%) — Laser-based medical device components used to deliver interstitial PDT treatment. - **Control software** (20%) — Patented IDOSE® software that manages light dose and treatment precision. - **Clinical development services** (25%) — Clinical studies and evidence generation for prostate cancer indications. - **Industrialization and manufacturing preparation** (15%) — Work to enable future series production and product launch. - Q-PRO® interstitial PDT treatment system - IDOSE® patented dose-control software - Laser-based photodynamic cancer therapy - Clinical development for localized prostate cancer - Platform adaptation for other solid tumors ## Customers SpectraCure’s direct customers are not end patients but healthcare providers, clinical investigators, and ultimately hospitals and specialist cancer centers that would adopt the Q-PRO® system after regulatory approval. In the current development phase, the company also works with research partners, reference clinics, and technology collaborators that support clinical validation and industrialization. - **Clinical investigators and reference clinics** (primary) — They run the prostate cancer studies and generate the clinical evidence needed for approval and adoption. - **Hospitals and cancer centers** (primary) — Future buyers of the Q-PRO® system for focal treatment of localized prostate cancer. - **Medical technology partners** (secondary) — They support product development, industrialization, and future manufacturing readiness. - **Licensing and commercialization partners** (secondary) — Potential partners for broader market access and technology monetization. - Urologists and clinical investigators running prostate cancer studies - Hospitals and specialist cancer centers as future users - Research institutions supporting clinical evidence generation - Medical technology partners involved in industrialization - Potential licensing or commercialization partners ## Geography SpectraCure is headquartered in Lund, Sweden, and its development work is anchored there. Its clinical and commercialization strategy is focused on North America and Europe, while industrialization work involves partners in the Netherlands and Switzerland. - **North America** (50%) — Target market for initial regulatory approval and commercialization - **Europe** (50%) — Target market for initial regulatory approval and commercialization - Headquartered in Lund, Sweden - Clinical studies run in North America and Europe - Initial market focus is North America and Europe - Industrialization work involves the Netherlands and Switzerland - Future commercialization depends on regulatory access in target markets ## Strategy SpectraCure’s strategy is to build clinical evidence for Q-PRO® in recurrent and primary localized prostate cancer, then use that evidence to support regulatory approval and commercialization. The company is also preparing the product for series production and working with external technology partners to make the system manufacturable at scale. - **Clinical validation in prostate cancer** (short-term) — Approval and adoption depend on demonstrating safety and efficacy in well-run studies. - **Regulatory pathway in target markets** (medium-term) — Commercial launch requires market authorization in North America and Europe. - **Industrialization and manufacturability** (medium-term) — The system must be ready for series production before commercialization. - **Platform expansion beyond prostate cancer** (long-term) — The same PDT approach may be adapted to other solid tumors over time. - Generate clinical evidence in recurrent prostate cancer - Expand into primary localized prostate cancer - Seek regulatory approval in North America and Europe - Prepare Q-PRO® for future series manufacturing - Use clinical publications to support adoption ## Risks SpectraCure’s main risks are tied to clinical development, regulatory approval, and the ability to secure commercialization or licensing agreements. As a development-stage medtech company, it also faces competition from alternative prostate cancer treatments and depends on external partners for parts of product development and future market access. - **Clinical development risk** [critical] — The business depends on proving that Q-PRO® is safe and effective in patient studies. - **Regulatory approval risk** [high] — Commercial launch cannot occur without market authorization in target regions. - **Licensing and commercialization risk** [high] — Future monetization may rely on licensing or partner agreements on acceptable terms. - **Competition from alternative treatments** [medium] — Other prostate cancer therapies may be more established, better funded, or easier to adopt. - **Partner dependency risk** [medium] — Industrialization and development rely on external collaborators and reference clinics. - Clinical studies may fail to show sufficient safety or efficacy - Regulatory approval is required before commercialization - Licensing or partner agreements may not materialize - Competing cancer treatments may prove more attractive - Dependence on external development and industrialization partners ## Accounting SpectraCure currently has no revenue from its main operations, so reported results are driven by development spending, grants, and limited ancillary income. Investors should watch how research grants are recognized, how related-party service income is recorded under IFRS 15, and how lease-related accounting under IFRS 16 affects cash flow presentation. - **IFRS 15 service revenue** — Affects reported other operating income - **Grant income recognition** — Affects timing of other operating income - **Related-party transactions** — Affects comparability of revenue and margins - **IFRS 16 lease accounting** — Affects operating vs financing cash flow presentation - No operating revenue from the core business yet - IFRS 15 applies mainly to administrative service income - Research grants are recognized over the related cost period - Related-party transactions affect other operating income - IFRS 16 changes operating and financing cash flow presentation --- *Last updated: 2026-08-11T04:04:55.899272+00:00*